CSL Vifor Investigator-Initiated Studies

Proposals studying the effects of treating iron deficiency / iron deficiency anemia using any of CSL Vifor ’s iron products should be in-line with the registered, indicated populations.

Intravenous iron products:

• Ferric carboxymaltose (Ferinject® / Injectafer®) in iron deficient patients ≥ 14 years of age
• Iron sucrose (Venofer®) in iron deficient patients ≥ 3 months of age

Oral iron products:

• Iron polymaltose (Maltofer® / Ferrum Hausmann®) in iron deficient patients of any age

IIS proposals in the Hyperkalemia area should aim at investigating the medical need in hyperkalemia or enhancing the medical and scientific knowledge of patiromer, including (but not limited to) investigations into patiromer’s mechanism of action, efficacy and safety, and effects beyond potassium.

Investigator-Initiated Study (IIS) proposals in the area of hyperphosphatemia should aim at investigating the clinical and societal benefit of treating hyperphosphatemia with calcium-free, iron-based phosphate binders in CKD patients on dialysis.

Hyperphosphatemia products:

• Sucroferric Oxyhydroxide (Velphoro®) is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).